Company intelligence / Profile preview

Intendis

Berlin, Berlin, Germany

Ownership: Private
Development stage: Other

Overview

Intendis was a specialized pharmaceutical company dedicated exclusively to the field of dermatology. Originally established as the dermatology business unit of Schering AG, the company focused on developing and marketing therapeutic solutions for skin conditions including acne, rosacea, and various forms of eczema. Its commercial portfolio featured prominent brands such as Finacea and Desonate. Following the acquisition of Schering AG by Bayer, Intendis operated as a subsidiary until it was fully integrated into Bayer HealthCare in 2011. The company's operations encompassed the entire value chain from research and development to global commercialization of topical dermatological treatments.

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Small molecule
Industry: Pharma

Beyond the preview

Go deeper on Intendis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intendis.

Explore the full profile